Home
/
Keros Therapeutics, Inc.
/
Financials
/
Quarterly
Keros Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Keros Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$14.12M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$18.17M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$211.19M
May 6, 2025
Q3
2025
Sep 30, 2024
$0
Nov 5, 2025
Q2
2025
Jun 30, 2024
$0
Aug 6, 2025
Q1
2025
Mar 31, 2024
$0
May 6, 2025
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$14.26M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$18.17M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$211.25M
May 6, 2025
Q3
2025
Sep 30, 2024
$388.0K
Nov 5, 2025
Q2
2025
Jun 30, 2024
$37.0K
Aug 6, 2025
Q1
2025
Mar 31, 2024
$83.0K
May 6, 2025
Q3
2024
Sep 30, 2023
$8.0K
Nov 6, 2024
Q2
2024
Jun 30, 2023
$0
Aug 7, 2024
Q1
2024
Mar 31, 2023
$0
May 8, 2024
Q3
2023
Sep 30, 2022
$0
Nov 6, 2023
Q2
2022
Jun 30, 2022
$0
Aug 4, 2022
Q3
2022
Sep 30, 2021
$0
Nov 3, 2022
Q2
2022
Jun 30, 2021
$100.0K
Aug 4, 2022
Q3
2021
Sep 30, 2020
$0
Nov 4, 2021
Q2
2021
Jun 30, 2020
$0
Aug 5, 2021
Q1
2020
Mar 31, 2020
$0
May 22, 2020
Q3
2020
Sep 30, 2019
$2.50M
Nov 10, 2020
Q2
2020
Jun 30, 2019
$2.50M
Aug 13, 2020
Q1
2020
Mar 31, 2019
$2.50M
May 22, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($7.28M)
Nov 5, 2025
Q3
2025
Jun 30, 2025
($30.70M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($30.70M)
Aug 6, 2025
Q2
2025
Mar 31, 2025
$148.45M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$148.45M
May 6, 2025
Q3
2025
Mar 31, 2025
$148.45M
Nov 5, 2025
Q3
2025
Sep 30, 2024
($52.96M)
Nov 5, 2025
Q3
2025
Jun 30, 2024
($45.26M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($45.26M)
Aug 6, 2025
Q3
2025
Mar 31, 2024
($43.11M)
Nov 5, 2025
Q1
2025
Mar 31, 2024
($43.11M)
May 6, 2025
Q2
2025
Mar 31, 2024
($43.11M)
Aug 6, 2025
Q3
2024
Sep 30, 2023
($39.44M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($37.51M)
Aug 7, 2024
Q3
2024
Jun 30, 2023
($37.51M)
Nov 6, 2024
Q1
2024
Mar 31, 2023
($35.80M)
May 8, 2024
Q2
2024
Mar 31, 2023
($35.80M)
Aug 7, 2024
Q3
2024
Mar 31, 2023
($35.80M)
Nov 6, 2024
Q3
2023
Sep 30, 2022
($23.51M)
Nov 6, 2023
Q2
2023
Jun 30, 2022
($27.27M)
Aug 7, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($15.38M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($39.82M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
$152.04M
May 6, 2025
Q3
2025
Sep 30, 2024
($58.66M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($50.44M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($48.48M)
May 6, 2025
Q3
2024
Sep 30, 2023
($43.28M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($41.34M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($38.87M)
May 8, 2024
Q3
2023
Sep 30, 2022
($27.98M)
Nov 6, 2023
Q2
2023
Jun 30, 2022
($30.73M)
Aug 7, 2023
Q1
2023
Mar 31, 2022
($24.13M)
May 4, 2023
Q3
2022
Sep 30, 2021
($20.20M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($15.54M)
Aug 4, 2022
Q1
2021
Mar 31, 2021
($15.77M)
May 5, 2022
Q3
2021
Sep 30, 2020
($11.95M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($10.91M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($10.50M)
May 6, 2021
Q3
2020
Sep 30, 2019
($2.33M)
Nov 10, 2020
Q2
2020
Jun 30, 2019
($2.65M)
Aug 13, 2020